Navigation Links
BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress
Date:5/23/2013

BOTHELL, Wash., May 23, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTC:BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced its participation at the Terrapinn World Stem Cells & Regenerative Medicine Congress 2013 this week in London.

(Logo: http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

Dr. Aby J. Mathew, BioLife's Senior Vice President and Chief Technology Officer, will make a presentation titled "Critical Stability and Biopreservation Considerations for Manufacturing, Storage and Clinical Delivery of Cell and Tissue Products," to the audience of executives and product development managers of commercial regenerative medicine companies. The presentation outlines the risk to clinical and commercial success of cell and tissue products due to stability limitations from the use of non-optimized storage, transport and cryopreservation freeze media. Comparative data illustrating the superior preservation efficacy of BioLife's HypoThermosol® storage and shipping media, and CryoStor® cryopreservation freeze media will be presented on relevant cell and tissue types.


'/>"/>

SOURCE BioLife Solutions, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioLife Solutions Completes First $1 Million Revenue Quarter
2. BioLife Solutions Appoints Rick Stewart To Board of Directors
3. BioLife Solutions Announces 2012 Full Year Results; 10th Consecutive Quarter of Record Revenue
4. SolutionStart Corp. Announces John Karagiannis as Vice President of Technology
5. Cardinal Health Specialty Solutions Launches PathWare™ Decision Support Transaction Solutions
6. At SIIM 2012 Siemens Healthcare Demonstrates Departmental IT Solutions That Help Administrators Increase Access while Managing Costs
7. Cardiosolutions, Inc. Receives FDA 510(k) Clearance for Dexterity™ Steerable Introducer
8. UBM Canon, the Global MedTech Authority, Partners with the World Medical Device Organization, WMDO, to Provide Medical Device Companies with Industry-Related Online Training Solutions
9. Ablative Solutions Completes $5.3M Series A Financing
10. DATATRAK Expands CDISC Registered Solutions Provider Standards
11. MedNet Solutions to Unveil Innovative New iMedNet EDC Features at The 48th DIA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... ., Aug. 22, 2014  Research presented at the ... therapy being developed by Hera Therapeutics Inc. combats three types ... of all cervical cancer. When tested in several ... HPV-18 and HPV-11 cells, according to Louise T. Chow ... the findings at the Seattle conference. ...
(Date:8/22/2014)... /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a ... technologies and products for advanced microarray diagnostics, today ... Service Agreement to contract with a UK-based company ... the initial phase of this agreement, SQI will ... of one of the customer,s assays, operational on ...
(Date:8/21/2014)... Ill. , Aug. 21, 2014 ... Baxter International Inc. today announced positive results from ... 855, an investigational, extended half-life recombinant factor VIII ... [Antihemophilic Factor (Recombinant)], which met its primary endpoint ... prophylaxis arm compared to the on-demand arm. ...
Breaking Medicine Technology:Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
... in combination with the most commonly used doses of ... patients with mixed dyslipidemiaORLANDO, Fla., March 29 Data ... TRILIPIX(R) (fenofibric acid) delayed-release capsules in combination with rosuvastatin ... TRILIPIX 135 mg in combination with rosuvastatin calcium 5 ...
... March 29 A new analysis from the,JUPITER ... the risk of venous thromboembolism (VTE) by 43% ... with low to normal cholesterol levels and elevated,high-sensitivity ... the 58th Annual American College of Cardiology Scientific ...
Cached Medicine Technology:New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 2New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 3New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 4New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 5CRESTOR(R) Reduced Risk of Blood Clots in the Veins 2CRESTOR(R) Reduced Risk of Blood Clots in the Veins 3CRESTOR(R) Reduced Risk of Blood Clots in the Veins 4
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 Mi40x ... uses university-proven research to show people how they can use ... muscle in only a matter of weeks has caught the ... “Ben Pakulski is one of the most well-known bodybuilders in ... the body he has today, that in itself is a ...
(Date:8/22/2014)... Paying tuition and other related educational ... year for four nurse educators pursuing advanced degrees, thanks ... Nursing Foundation for Nursing Education . This year’s recipients ... more than in 2013, thanks to these named NLN ... Isaac Marcil Endowment Funds, both donated by Kathy Mershon; ...
(Date:8/22/2014)... Wisconsin (PRWEB) August 22, 2014 Mueller ... for Plantar Fasciitis, an exciting new product that provides ... you to stay active while you heal. The package ... is truly a new technology – it is not ... , FasciaDerm® PFTape™ System for Plantar Fasciitis ...
(Date:8/22/2014)... A new study of self-awareness by Kessler Foundation ... may be able to improve their self-awareness through ... of print on July 2 in NeuroRehabilitation ... D. Chiaravalloti & John DeLuca: Metacognitive knowledge and ... 10.3233/NRE-141113). Self-awareness is one,s ability to recognize cognitive ...
(Date:8/22/2014)... 2014 Menstrual leaks risk stains and ... Fla., decided that there needed to be a better ... and producible in design variations, the Safety Net optimizes ... which avoids embarrassment and promotes peace of mind. The ... , The original design was submitted to the Fort ...
Breaking Medicine News(10 mins):Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2
... gene (MTDH) plays a role in both cancer metastasis ... Press in the January 6th issue of the journal ... therapeutic target for high risk breast cancers. , "Most ... succumb to recurrent tumors that spread to distant vital ...
... , The Fifth International Conference on Cell Therapy ... on stem cells for non-cardiac organ injury. The session ... disease and diabetes, bone marrow cells for stroke patients, ... , Highlights from other sessions include the first human ...
... in the U.S. each year have been exposed to alcohol or ... by the National Center on Substance Abuse and Child Welfare. If ... remain in foster care longer, and chances are very low that ... study led by Joseph P. Ryan, a faculty member in the ...
... PR Newswire Staff Volunteer Time As Part ... InitiativeCLEVELAND, Jan. 5 Ronald McDonald House of ... two non-profit organizations serving the Cleveland community, were ... hours from PR Newswire,s Cleveland staff in 2008, ...
... cost Medicaid hundreds of millions of dollars annually in ... could not only improve outcomes but also save substantial ... examined records of nearly 150,000 people in six states. ... more than they think," said Robin E. Clark, PhD, ...
... OF PLASTIC SURGEONSARLINGTON HEIGHTS, Ill., Jan. 5 The ... Plastic Surgeons:Can The US Really Cut Health Care Spending? ... is one of the strongest sectors of the ailing ... health care spending is not probable. The author, who ...
Cached Medicine News:Health News:Gene plays dual role in breast cancers with poor prognosis 2Health News:Conference on cell therapy includes new session on stem cells for non-cardiac organ injury 2Health News:'Recovery coaches' effective in reducing number of babies exposed to drugs 2Health News:'Recovery coaches' effective in reducing number of babies exposed to drugs 3Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 2Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 3Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 4Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 5Health News:Substance abuse adds millions to Medicaid's total health care costs 2Health News:Substance abuse adds millions to Medicaid's total health care costs 3Health News:Plastic and Reconstructive Surgery...In Brief 2Health News:Plastic and Reconstructive Surgery...In Brief 3
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Kleinert-Kutz Single Skin Hook, Large...
Medicine Products: